Literature DB >> 26518748

Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.

Kieron Dunleavy1, Stefania Pittaluga2, Margaret Shovlin3, Mark Roschewski4, Catherine Lai3, Seth M Steinberg4, Elaine S Jaffe2, Wyndham H Wilson3.   

Abstract

Entities:  

Keywords:  EPOCH; dose-adjusted; phase II; systemic aplastic large cell lymphoma

Mesh：

Substances：

Year:  2015        PMID： 26518748      PMCID： PMC4697904          DOI： 10.3324/haematol.2015.131151

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

Authors:  Wyndham H Wilson; Sin-Ho Jung; Pierluigi Porcu; David Hurd; Jeffrey Johnson; S Eric Martin; Myron Czuczman; Raymond Lai; Jonathan Said; Amy Chadburn; Dan Jones; Kieron Dunleavy; George Canellos; Andrew D Zelenetz; Bruce D Cheson; Eric D Hsi
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

Review 2.  New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.

Authors:  Kieron Dunleavy; Richard L Piekarz; Jasmine Zain; John E Janik; Wyndham H Wilson; Owen A O'Connor; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

Review 3.  Peripheral T-cell lymphoma.

Authors:  Francine M Foss; Pier Luigi Zinzani; Julie M Vose; Randy D Gascoyne; Steven T Rosen; Kensei Tobinai
Journal:  Blood       Date:  2011-04-14       Impact factor: 22.113

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.

Authors:  David Sibon; Marion Fournier; Josette Brière; Laurence Lamant; Corinne Haioun; Bertrand Coiffier; Serge Bologna; Pierre Morel; Jean Gabarre; Olivier Hermine; Anne Sonet; Christian Gisselbrecht; Georges Delsol; Philippe Gaulard; Hervé Tilly
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

6.  High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining.

Authors:  L Lamant; F Meggetto; T al Saati; L Brugières; B B de Paillerets; N Dastugue; A Bernheim; H Rubie; M J Terrier-Lacombe; A Robert; F Rigal; D Schlaifer; M Shiuta; S Mori; G Delsol
Journal:  Blood       Date:  1996-01-01       Impact factor: 22.113

7.  Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.

Authors:  Wyndham H Wilson; Kieron Dunleavy; Stefania Pittaluga; Upendra Hegde; Nicole Grant; Seth M Steinberg; Mark Raffeld; Martin Gutierrez; Bruce A Chabner; Louis Staudt; Elaine S Jaffe; John E Janik
Journal:  J Clin Oncol       Date:  2008-03-31       Impact factor: 44.544

8.  Low-intensity therapy in adults with Burkitt's lymphoma.

Authors:  Kieron Dunleavy; Stefania Pittaluga; Margaret Shovlin; Seth M Steinberg; Diane Cole; Cliona Grant; Brigitte Widemann; Louis M Staudt; Elaine S Jaffe; Richard F Little; Wyndham H Wilson
Journal:  N Engl J Med       Date:  2013-11-14       Impact factor: 91.245

9.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Authors:  Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

10.  Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.

Authors:  Francesco d'Amore; Thomas Relander; Grete F Lauritzsen; Esa Jantunen; Hans Hagberg; Harald Anderson; Harald Holte; Anders Österborg; Mats Merup; Peter Brown; Outi Kuittinen; Martin Erlanson; Bjørn Østenstad; Unn-Merete Fagerli; Ole V Gadeberg; Christer Sundström; Jan Delabie; Elisabeth Ralfkiaer; Martine Vornanen; Helle E Toldbod
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  7 in total

1.  ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project.

Authors:  Andrei Shustov; Maria Elena Cabrera; Monica Civallero; Monica Bellei; Young Hyeh Ko; Martina Manni; Tetiana Skrypets; Steven M Horwitz; Carmino Antonio De Souza; John A Radford; Sabela Bobillo; Maria Virginia Prates; Andrés J M Ferreri; Carlos Chiattone; Michele Spina; Julie M Vose; Annalisa Chiappella; Daniele Laszlo; Dario Marino; Caterina Stelitano; Massimo Federico
Journal:  Blood Adv       Date:  2021-02-09

Review 2.  Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum.

Authors:  John T Sandlund; Mike G Martin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 3.  Peripheral T-Cell Lymphomas: Therapeutic Approaches.

Authors:  David Sibon
Journal:  Cancers (Basel)       Date:  2022-05-08       Impact factor: 6.575

Review 4.  Diagnosis and treatment of CD20 negative B cell lymphomas.

Authors:  Tasleem Katchi; Delong Liu
Journal:  Biomark Res       Date:  2017-02-07

Review 5.  T-cell lymphomas, a challenging disease: types, treatments, and future.

Authors:  Helen Ma; Maher Abdul-Hay
Journal:  Int J Clin Oncol       Date:  2016-10-14       Impact factor: 3.402

6.  Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL.

Authors:  Milos D Miljkovic; Christopher Melani; Stefania Pittaluga; Rahul Lakhotia; Nicole Lucas; Allison Jacob; Erik Yusko; Elaine S Jaffe; Wyndham H Wilson; Mark Roschewski
Journal:  Blood Adv       Date:  2021-10-26

7.  Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.

Authors:  Yoshinobu Maeda; Hisakazu Nishimori; Isao Yoshida; Yasushi Hiramatsu; Masatoshi Uno; Yasufumi Masaki; Kazutaka Sunami; Taro Masunari; Yuichiro Nawa; Hiromichi Yamane; Hiroshi Gomyo; Tsutomu Takahashi; Tomofumi Yano; Keitaro Matsuo; Koichi Ohshima; Shigeo Nakamura; Tadashi Yoshino; Mitsune Tanimoto
Journal:  Haematologica       Date:  2017-09-29       Impact factor: 9.941
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.